Get the Stockscreener App
27.96
3.79%
-1.10
After Hours:
28.52
0.56
+2.00%
Biodesix Inc stock is traded at $27.96, with a volume of 102.14K.
It is down -3.79% in the last 24 hours and up +6.80% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
See More
Previous Close:
$29.06
Open:
$29.3
24h Volume:
102.14K
Relative Volume:
1.03
Market Cap:
$295.01M
Revenue:
$96.10M
Net Income/Loss:
$-31.96M
P/E Ratio:
-6.9437
EPS:
-4.0267
Net Cash Flow:
$-25.27M
1W Performance:
-4.05%
1M Performance:
+6.80%
6M Performance:
+82.03%
1Y Performance:
+270.82%
1-Day Range:
$27.52
$29.99
1-Week Range:
$26.33
$30.13
52-Week Range:
$5.26
$31.97
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, NTRA, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
27.96 | 307.04M | 96.10M | -31.96M | -25.27M | -4.0267 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
Biodesix Inc (BDSX) Shares Fall 4.2% -- What GF Score of 50 Tells Investors - GuruFocus
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests - Yahoo Finance
HC Wainwright & Co. maintains Buy rating on Biodesix, $38 price target - TradingView
Biodesix Stock Price Forecast. Should You Buy BDSX? - StockInvest.us
Biodesix, Inc. (BDSX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease Monitoring - marketscreener.com
Biodesix, Inc. Advances Two Complementary Approaches to Molecular Residual Disease Monitoring - marketscreener.com
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher - Yahoo Finance
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher - Investing.com
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher By Investing.com - Investing.com India
Biodesix Announces Progress on Tumor-Informed and Tumor-Naïve MRD Programs with Bio-Rad and Thermo Fisher - Quiver Quantitative
Biodesix Advances Two Complementary Approaches To Molecular Residual Disease (Mrd) Monitoring - TradingView
After cancer treatment, monitoring may reach patients without tumor tissue - Stock Titan
Biodesix (BDSX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Biodesix, Inc.(NasdaqGM: BDSX) added to S&P Global BMI Index - marketscreener.com
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet - Eastern Progress
Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism - Yahoo Finance
Biodesix Inc (NASDAQ: BDSX) Stock Price, News & Analysis - kalkine.ca
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings - Stock Titan
A Look at Biodesix Inc (BDSX) After 3.5% Gain -- GF Value $21.14 vs Price $26.96 - GuruFocus
Opaleye Management Inc. Cuts Position in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX) - Seeking Alpha
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Analysts - marketbeat.com
BlackRock Inc. Invests $970,000 in Biodesix, Inc. $BDSX - marketbeat.com
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? - Eastern Progress
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak - ChartMill
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High? - Yahoo Finance
Biodesix Inc (BDSX) Stock Up 9.0% but GF Value Says Overvalued -- GF Score: 51/100 - GuruFocus
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - qz.com
BDSX: Biodesix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - Prime Publishers, Inc.
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionCEO Earnings Statement - vinanet.vn
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingGuidance Accuracy Score - vinanet.vn
46,989 Shares in Biodesix, Inc. $BDSX Purchased by GSA Capital Partners LLP - MarketBeat
AIGH Capital Management LLC Acquires New Stake in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportVol Target Rebalance - vinanet.vn
Walleye Capital LLC Makes New $1.68 Million Investment in Biodesix, Inc. $BDSX - MarketBeat
Sei Investments Co. Makes New Investment in Biodesix, Inc. $BDSX - MarketBeat
BDSX Q2 2026 Earnings: EPS Beats Estimates by 22.85% as Loss NarrowsEarnings Preview - vinanet.vn
BDSX | Biodesix, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Australia
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
BDSX Q2 2026 Earnings: Narrower Loss Beats Estimates as Shares Dip 1.78Earnings Yield Spread - Vinanet
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - marketscreener.com
Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares - Stock Titan
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Australia
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock - MarketBeat
Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares - MarketBeat
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biodesix Inc Stock (BDSX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCHULER JACK W | Emeritus Director |
Aug 10 '26 |
Buy |
24.25 |
13,900 |
337,029 |
527,110 |
| SCHULER JACK W | Emeritus Director |
Aug 11 '26 |
Buy |
24.01 |
13,700 |
328,911 |
540,810 |
| Pestano Gary Anthony | Chief Development Officer |
Feb 23 '26 |
Sale |
12.78 |
556 |
7,103 |
10,359 |
| O'Kane Kieran | Chief Commercial Officer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
9,819 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
16,231 |
| Vazquez Chris | Chief Accounting Officer |
Feb 23 '26 |
Sale |
12.78 |
211 |
2,696 |
1,586 |
| Hutton Scott | President & CEO |
Feb 23 '26 |
Sale |
12.78 |
1,490 |
19,036 |
48,767 |
0.99%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):